NEUROPATHIC PAIN · White paper
Neuropathic Pain Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About neuropathic pain — and why its trials are hard
Neuropathic pain arises as a direct consequence of a lesion or disease of the somatosensory nervous system, producing burning, electric, or shock-like pain that is often chronic and resistant to conventional analgesics. Common subtypes include diabetic peripheral neuropathy, postherpetic neuralgia, and trigeminal neuralgia, and prevalence rises with age and with conditions such as diabetes and cancer. First-line pharmacotherapy targets central and peripheral sensitization: the alpha-2-delta calcium-channel ligands pregabalin and gabapentin, the SNRI duloxetine, tricyclic antidepressants such as amitriptyline, and topical agents (lidocaine 5% patch, high-concentration capsaicin 8% patch). Pivotal trials measure pain intensity reduction on numeric or visual analog scales, responder rates, patient-reported outcomes, and functional improvement. Neuropathic pain drug development is notoriously difficult: high and rising placebo response, heterogeneous pain etiologies, small underpowered studies, poorly defined endpoints, and recruitment failures repeatedly undermine trials, and observed efficacy estimates have trended downward as methodology has become more rigorous, demanding careful patient selection and enriched designs.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Gabapentin (Neurontin) | 2002 | Postherpetic neuralgia (alpha-2-delta calcium-channel ligand; originally approved 1993 for epilepsy) | Pivotal PHN trials | Weekly mean pain score (11-point numeric scale) | Significant pain reduction vs placebo; responder rates ~29-34% vs ~12-14% placebo |
| Pregabalin (Lyrica) | 2004 | Diabetic peripheral neuropathy and postherpetic neuralgia (alpha-2-delta ligand) | Pivotal DPN and PHN trials | Change in mean pain score (numeric rating scale) | Significant dose-dependent pain reduction vs placebo across DPN/PHN |
| Duloxetine (Cymbalta) | 2004 | Diabetic peripheral neuropathic pain (serotonin-norepinephrine reuptake inhibitor) | Pivotal DPNP trials | 24-hour average pain severity | Significant reduction in average daily pain vs placebo (60 mg) |
| Lidocaine 5% patch (Lidoderm) | 1999 | Postherpetic neuralgia (topical sodium-channel blocker) | PHN patch trials | Pain relief / allodynia reduction | Topical relief of PHN pain vs placebo patch (magnitude modest, unverified exact value) |
| Capsaicin 8% patch (Qutenza) | 2009 | Postherpetic neuralgia (2009); expanded to diabetic peripheral neuropathy of the feet (2020) (TRPV1 agonist) | PHN pivotal trials; DPN program | Percent change in numeric pain rating over weeks 2-8 | Single 60-minute application produced significant pain reduction vs control patch |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in neuropathic pain development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Donepezil — NCT01743976 | Terminated | Failure to recruit subjects (added to gabapentin/pregabalin background therapy) |
| Ramelteon — NCT00753623 | Terminated | Recruitment did not accrue as expected |
| Oxytocin — NCT02100956 | Terminated | Slow recruitment during the pandemic and lack of funding |
Choosing the right endpoint
Primary endpoints that matter in neuropathic pain trials
- Pain intensity reduction — Change on Numeric Rating Scale (NRS) or Visual Analog Scale (VAS); primary efficacy measure
- Responder rate (>=30% / >=50% pain reduction) — Proportion achieving clinically meaningful pain relief
- Patient-reported outcomes — Capture the patient's perception of treatment impact on pain and daily activities
- Quality of life — Standardized questionnaires assessing overall well-being and life satisfaction
- Functional improvement — Changes in ability to perform daily tasks, indicating practical benefit
How iNGENū runs neuropathic pain trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Neuropathic Pain clinical trials — FAQs
What are the first-line drugs for neuropathic pain?
Why do so many neuropathic pain trials fail?
Why have measured drug efficacy estimates declined over time?
Ready to discuss your neuropathic pain trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal